So, like, you wanna keep up with all the cool stuff happening in biotech, right? Well, sign up for our biotech newsletter and get all the juicy deets straight to your inbox. Trust me, you won’t wanna miss out on this stuff.
Yo, good morning peeps! We got a bunch of news to chat about today, like GLP-1 drugs, compounding, and how biotechs are dealing with the FDA. Let’s dive in, shall we?
So, here’s the lowdown for today:
• Abeona Therapeutics got the FDA’s stamp of approval for their cell-based gene therapy for folks with recessive dystrophic epidermolysis bulosa. It’s a rare skin condition that causes some gnarly blistering wounds. The therapy will be known as Zevaskyn. Nice!
• It’s earnings season, baby! Pfizer, Regeneron, AstraZeneca, Novartis, Incyte, and Verona Pharma all dropped their financial reports for the first quarter. Talk about a busy morning!
So, guess what? The game has changed for GLP-1 compounding. No more shortages for branded drugs, and compounding pharmacies can’t offer those cheaper knock-offs anymore. But, here’s the kicker – patients who relied on compounded drugs are kinda left in a pickle now. Some telehealth companies that dished out compounded GLP-1s have vanished into thin air. Others are playing risky games, like messing with prescriptions or pushing stockpiling of the old stuff. It’s a mess, really.
Novo Nordisk is stepping up their game by selling their lower-priced Wegovy straight to patients. They’ve inked deals with telehealth companies like Hims & Hers and Ro. Smart move, Novo!
On the FDA front, it’s a tale of two biotechs. Stealth BioTherapeutics got hit with a delay in the review of their Barth syndrome treatment. Tough break. But Capricor Therapeutics is all good, with the FDA breezing through their cell therapy for Duchenne muscular dystrophy. Kudos to Capricor!
Oh, and check this out – new data shows that one dose of the HPV vaccine is just as effective as two doses. Mind blown, right? This could be a game-changer for getting more kids vaccinated. Experts are loving this news, calling it “phenomenal.” Way to go, science!
Now, let’s talk about Marty Makary. Dude was supposed to lead the FDA and shield it from vaccine criticism, but he’s singing a different tune now. Makary is raising eyebrows with his scrutiny of vaccines and vaccination policies. What’s he up to? Who knows, man.
The pharmaceutical industry’s rep is taking a hit, especially when it comes to drug pricing. Patient advocacy groups ain’t too thrilled with drug companies these days. Pricing transparency? Fair pricing? Yeah, not really their strong suit, it seems.
And hey, if you’re into some light reading:
• A tariff war is brewing, and Novo ain’t too happy about it.
• A new House bill could shake things up for pharma companies’ tax deductions.
So, that’s the scoop for today, folks. Stay tuned for more biotech adventures. Peace out!
